Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
Pharma and BioTech Daily
Pharma and Biotech Daily: Pfizer's Comeback, FDA Approvals, and Industry Updates
•
Pharma Daily
•
Season 1
•
Episode 514
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Pfizer has made a comeback in the obesity market with the acquisition of Metsera for $4.9 billion, rejuvenating its portfolio after facing challenges with three discontinued assets. Meanwhile, Stealth BioTherapeutics has received expedited FDA approval for the first-ever treatment for Barth syndrome, and Sanofi's decision on their oral multiple sclerosis drug has been postponed to December. The ACIP committee has expressed concerns about a lack of knowledge and experience within the reconstituted committee. Biotility offers industry-recognized credentials to advance bioscience careers, Novartis is exploring ways to reduce drug costs in the US, and Merck has received approval for a subcutaneous formulation of Keytruda. Stay tuned for more updates on the psychedelics space, rare disease treatments, and other developments in the biopharmaceutical industry.